This is the first report of chloroquine (Aralen*) dihydrochloride as a local anesthetic and anticoagulant. Chloroquine is chemically unrelated to novocaine (procaine hydrochloride) or xylocaine (lidocaine) and, when injected intradermally or subcutaneously, produces prompt local anesthesia adequate for the performance of dermatological surgery. Prolonged bleeding occurs at the sites of injections and scalpel surgery.
Chloroquine (Aralen) was first introduced in this country as a result of the widespread screening program for antimalarial compounds undertaken during World War II.1 More recently, it has been employed therapeutically in a variety of dermatological conditions such as discoid lupus erythematosus2 and lichen planus.3 Thies4 has reported on the treatment of chronic discoid lupus erythematosus by local infiltration. In his cases, however, novocaine was injected simultaneously.
Chloroquine (7-chloro-4-[4-diethylamino-1-methylbutylamino] quinoline) is made available for parenteral administration as chloroquine (Aralen) dihydrochloride. The material used in this study was obtained in 3 cc. ampules,
MANDEL EH. A New Local Anesthetic with Anticoagulant Properties: Chloroquine (Aralen) Dihydrochloride. AMA Arch Derm. 1960;81(2):260–263. doi:10.1001/archderm.1960.03730020096015
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: